Lv1
20 积分 2024-12-10 加入
Objective criteria for statistical assessments of cross validation of bioanalytical methods
14天前
已完结
Mitigation of pre-existing immunogenicity in ADA method development
15天前
已完结
Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody
2个月前
已完结
Tebentafusp: First Approval
2个月前
已完结
Discovery and Evaluation of DA-302168S as an Efficacious Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist
2个月前
已完结
Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products
2个月前
已完结
Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products
3个月前
已完结
Anti-drug Antibody Validation Testing and Reporting Harmonization Addendum
3个月前
已完结
A Non-Normal Bayesian Model for the Estimation and Comparison of Immunogenicity Screening Assay Cut-Points
5个月前
已完结
Cut Point in Immunogenicity Testing: A Flawed Concept We Can Live Without
6个月前
已完结
皖公网安备34019202002308
